scholarly journals Concomitant occurrence of genetically distinct Hodgkin lymphoma and primary mediastinal lymphoma

2021 ◽  
Vol 9 (8) ◽  
Author(s):  
Sydney Dubois ◽  
Philippe Ruminy ◽  
Elodie Bohers ◽  
Pierre‐Julien Viailly ◽  
Liana Veresezan ◽  
...  
Keyword(s):  
Hodgkin Lymphoma ◽  
Mediastinal Lymphoma ◽  
Primary Mediastinal Lymphoma

Primary Mediastinal Lymphoma

2004 ◽  
Vol 28 (6) ◽  
pp. 782-789 ◽  
Author(s):  
Ukihide Tateishi ◽  
Nestor L. M??ller ◽  
Takeshi Johkoh ◽  
Yasushi Onishi ◽  
Yasuaki Arai ◽  
...  
Keyword(s):  
Mediastinal Lymphoma ◽  
Primary Mediastinal Lymphoma

Has the 67Ga-SPET a Role in Monitoring Hodgkin and Primary Mediastinal Lymphoma in the PET-FDG Age?.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4643-4643 ◽  
Author(s):  
Isabella Palumbo ◽  
Giorgia Desantis ◽  
Barbara Palumbo ◽  
Lorenzo Falchi ◽  
Paola Cerroni ◽  
...  
Keyword(s):  
Disease Free Survival ◽  
Nuclear Imaging ◽  
Diagnostic Value ◽  
Residual Tumour ◽  
Peripheral Blood Stem Cells ◽  
Persistent Disease ◽  
Mediastinal Lymphoma ◽  
Mediastinal Disease ◽  
Post Therapy ◽  
Primary Mediastinal Lymphoma

Abstract Background and aims Present data indicate that FDG-PET has a superior accuracy than gallium scan (Ga-S) in staging and post-therapy restaging of malignant lymphomas. However in Hodgkin’s lymphoma (HL) with a predominant mediastinal involvement and in primary mediastinal lymphoma (ML), this latter, less expensive, nuclear imaging technique might still have a diagnostic value. The aims of this prospective study were to assess: the accuracy of SPET Ga-S in detecting residual tumour in the upper diaphragm nodal regions mainly in the mediastinal site and its predictive value in terms of disease free survival (DFS) and overall survival (OS). Methods Since 1989, 68 patients (pts) with HL (60) or ML (8) were enrolled: 24 male and 44 female. Median age was 28 (range 12-80) years. Ann Arbor stage distribution was: stage IIA in 18 pts, IIB in 23 pts, IIIA in 4 pts, IIIB in 6 pts, IVA in 4 pts and IVB in 13 pts. Histology subgroups included 43 SN, 11 CM, 1 DL, 2 LP, 3 unclassified HL and 8 large B-cell ML. Bulky mediastinal disease was detected in 22 HL and all of ML cases. 44 patients received conventional chemotherapy, 4 non-myeloablative and 20 myeloablative chemotherapy with peripheral blood stem cells support because of unfavourable disease or resistant or relapsing to primary treatment disease. Ga-SPET was performed in all patients 72 hours after the intravenous injection of 370 MBq (8–10 mCi) of 67Ga cirate. SPET data acqusiton included a 360° rotation, with 60 projections at rate of 20 s per projection. The matrix size was 64x64 and a Butterworth filter (0.4–0.6) was used. Results A total of 107 Ga-SPET/TC restaging were obtained after chemotherapy and/or chemo-radiotherapy completion in 64/68 evaluable pts. Despite 84/107 CT evaluations were suggestive of persistent disease in the mediastinal region, 61/107 simultaneous Ga-SPET exams were negative. Instead Ga-SPET indicated the presence of active disease only in 5 cases although the CT was interpreted as negative. Concordant results were documented in the remaining 41 evaluations. The difference in the final post-therapy findings between Ga-SPET and TC were less frequent in upper diaphragm nodal region other than mediastinum, with concordant and discordant results respectively in 51/71 and 20/71 scans. Sensitivity, specificity and accuracy were 89%, 93% and 92% for the Ga-SPET, while they were 100%, 27% and 37% for the CT when the mediastinal area was considered. After a median follow-up of 34 (4–138) months, DFS and OS for patients with a positive Ga-SPET at the end of treatment program were 9 (2–57) and 24,5 (9–67) months, respectively. In contrast, the Corresponding figures have not been reached for patiens with a negative Ga-SPET after a median time of 31,5+ (3–136) months and 49,5+ (4–144) monhs respectively. The median values of DSF and OS of patients with a CT compatible with absent or persistent disease have not been reached at 31+ (3–89) vs 27+ (3–136) months and 46+ (11–108) vs 40+ (4–144) months. Conclusions Thus, Ga-SPET is still a useful, sensitive and not expensive method to determine the presence of eventual active post-therapy disease in the mediastinum.

scholarly journals Primary plasmacytoma involving mediastinal lymph nodes: A diagnostic mimicry of primary mediastinal lymphoma

2016 ◽  
Vol 9 (1) ◽  
pp. 26-29 ◽  
Author(s):  
Karma Z. Salem ◽  
Taiga Nishihori ◽  
Mohamed A. Kharfan-Dabaja ◽  
Pedro Horna ◽  
Melissa Alsina
Keyword(s):  
Lymph Nodes ◽  
Mediastinal Lymph Nodes ◽  
Mediastinal Lymphoma ◽  
Primary Mediastinal Lymphoma

Tracheobronchial Obstruction Caused by Primary Mediastinal Lymphoma

2017 ◽  
Vol 53 (4) ◽  
pp. 206
Author(s):  
María Luisa Valle Feijoo ◽  
Violeta Turcu ◽  
Fernando Iglesias Río ◽  
Ceferino Gutiérrez Mendiguchia
Keyword(s):  
Mediastinal Lymphoma ◽  
Tracheobronchial Obstruction ◽  
Primary Mediastinal Lymphoma

scholarly journals The First Experience of Treatment of Patients with Primary Mediastinal Lymphoma Using the R-m-NHL-BFM-90/R-EPOCH Protocol

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5391-5391
Author(s):  
Nelly Gabeeva ◽  
Daria Koroleva ◽  
Anastasya Belyaeva ◽  
Anna Smolyaninova ◽  
Natalia G. Chernova ◽  
...  
Keyword(s):  
Complete Remission ◽  
Treatment Plan ◽  
Hematologic Toxicity ◽  
Hematopoietic Stem ◽  
Number Of Patients ◽  
Mediastinal Lymphoma ◽  
Pet Ct ◽  
Mediastinal Disease ◽  
Primary Mediastinal Lymphoma

Abstract Background: Primary mediastinal lymphoma (PML) is an aggressive, but curable disease. Given the rarity of disease there is no consensus on the most effective program. The most encouraging results with R-DA-EPOCH program (Dunleavy K. et al, 2013) demonstrated high response rate and improved long-term event-free (EFS) and overall survival (OS) without radiotherapy. However, in the real world setting we still face a very difficult treatment decision: on the one hand, due to increasing treatment-related toxicities about 20% of patients (pts) didn`t complete the treatment plan, on the other, approximately 10% of patients had disease progression or relapse. Based on our own successful experience of treating aggressive B-cell lymphomas by using the previously published R-m-NHL-BFM-90 protocol, we used a strategy of intensive induction of remission (blocks A, B), followed by de-escalation of therapy with 2 or 4 courses of R-EPOCH depending of interim PET/CT (iPET/CT) results. Here we report the first results of the toxicity and efficacy assessment of the response-adapted program R-m-NHL-BFM-90/R-EPOCH for patients with untreated primary mediastinal lymphoma. Methods: Eleven previously untreated patients (pts) with PML underwent R-m-NHL-BFM-90/R-EPOCH treatment between October 2004 and July 2015 in Federal State Budgetary Organization «National Research Center for Hematology of Russian Federation Ministry of Healthcare»; median age 34 years old (range 24-50); M\F=2\9; Ann Arbor stage >I in 11 (100%). All the patients had one or more adverse factors (bulky mediastinal disease>10 cm in 10 pts, soft tissues involvement in 7 pts, breast in 4 pts; elevated lactate dehydrogenase level in 7 pts, pleural effusion in 5 pts). The treatment plan consisted of: (i) pre-phase (dexamethasone and cyclophosphamide); (ii) induction of remission (courses A and B of NHL-BFM-90 program that was modified in the following way: the dose of methotrexate was reduced to 1500mg/m2 (12 h) in course A, doxorubicin in dose 50mg\m2 was added on the third day of course A); (iii) consolidation with R-EPOCH without dose escalation (2 courses in pts with negative iPET/CT (DS1-3) and 4 courses in pts with positive iPET/CT (DS 4-5)). Results: All the patients completed the treatment plan. Hematologic toxicity grade 3-4 was observed only during the induction therapy, mainly after block A. After the induction with R-m-NHL-BFM-90 8 out of 11 patients (72%) were iPET/CT-negative and received 2 additional courses of R-EPOCH; 3 out of 11 patients (28%) were iPET/CT-positive and received 4 additional courses of R-EPOCH. Only 1 patient`s response was assessed as DS4 at the end-of-treatment PET/CT. She received autologous transplantation of hematopoietic stem cells and has now been in complete remission for 12 months. With a median follow-up of 10 months (range 1-29) all the patients are alive in complete remission. Conclusions: Despite a small number of patients and a short follow-up period, our results suggest that the response-adapted strategy of treatment is a reasonable option for PML patients, even in high risk of treatment failure. Disclosures No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document